The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
Abstract
Background Decreased systolic function is central to the pathogenesis of heart failure in millions of patients worldwide, but mechanism-related adverse effects restrict existing inotropic treatments. This study tested the hypothesis that omecamtiv mecarbil, a selective cardiac myosin activator, will augment cardiac function in human beings.Methods In this dose-escalating, crossover study, 34 healthy men received a 6-h double-blind intravenous infusion of omecamtiv mecarbil or placebo once a week for 4 weeks. Each sequence consisted of three ascending omecamtiv mecarbil doses (ranging from 0·005 to 1·0 mg/kg per h) with a placebo infusion randomised into the sequence. Vital signs, blood samples, electrocardiographs (ECGs), and echocardiograms were obtained before, during, and after each infusion. The primary aim was to establish maximum tolerated dose (the highest infusion rate tolerated by at least eight participants) and plasma concentrations of omecamtiv mecarbil; secondary aims were evaluation of pharmacodynamic and pharmacokinetic characteristics, safety, and tolerability. This study is registered at ClinicalTrials.gov, number NCT01380223.Findings The maximum tolerated dose of omecamtiv mecarbil was 0·5 mg/kg per h. Omecamtiv mecarbil infusion resulted in dose-related and concentration-related increases in systolic ejection time (mean increase from baseline at maximum tolerated dose, 85 [SD 5] ms), the most sensitive indicator of drug effect (r(2)=0·99 by dose), associated with increases in stroke volume (15 [2] mL), fractional shortening (8% [1]), and ejection fraction (7% [1]; all p<0·0001). Omecamtiv mecarbil increased atrial contractile function, and there were no clinically relevant changes in diastolic function. There were no clinically significant dose-related adverse effects on vital signs, serum chemistries, ECGs, or adverse events up to a dose of 0·625 mg/kg per h. The dose-limiting toxic effect was myocardial ischaemia due to excessive prolongation of systolic ejection time.Interpretation These first-in-man data show highly dose-dependent augmentation of left ventricular systolic function in response to omecamtiv mecarbil and support potential clinical use of the drug in patients with heart failure.Funding Cytokinetics Inc.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Omecamtiv mecarbil (OM) is a myosin activator that enhances systolic function in patients with HFrEF by augmenting actin-myosin interaction in the sarcomere.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [84]
Citations
Cites
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors/Task Force Members, Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,512
Authors/Task Force Members, Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Stromberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn309 · Cited by 2,696
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192666 · Cited by 1,359
Systolic Time Intervals in Heart Failure in Man
WEISSLER, A. M., HARRIS, W. S., & SCHOENFELD, C. D. (1968) · Circulation · doi:10.1161/01.cir.37.2.149 · Cited by 1,217
Mebazaa, A., Nieminen, M. S., Packer, M., Cohen-Solal, A., Kleber, F. X., Pocock, S. J., Thakkar, R., Padley, R. J., Põder, P., Kivikko, M., et al. (2007) · JAMA · doi:10.1001/jama.297.17.1883 · Cited by 994
A critical review of the systolic time intervals.
Lewis, R. P., Rittogers, S. E., Froester, W. F., & Boudoulas, H. (1977) · Circulation · doi:10.1161/01.cir.56.2.146 · Cited by 624
A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure
Cohn, J. N., Goldstein, S. O., Greenberg, B. H., Lorell, B. H., Bourge, R. C., Jaski, B. E., Gottlieb, S. O., McGrew, F., DeMets, D. L., & White, B. G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812173392503 · Cited by 613
Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Malik, F. I., Hartman, J. J., Elias, K. A., Morgan, B. P., Rodriguez, H., Brejc, K., Anderson, R. L., Sueoka, S. H., Lee, K. H., Finer, J. T., et al. (2011) · Science · doi:10.1126/science.1200113 · Cited by 584
Self-citationHeart failure etiology and response tomilrinone in decompensated heart failure
Felker, G. M., Benza, R. L., Chandler, A. B., Leimberger, J. D., Cuffe, M. S., Califf, R. M., Gheorghiade, M., & O’Connor, C. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02968-6 · Cited by 515
Cited by
Biobank-driven genomic discovery yields new insight into atrial fibrillation biology
Nielsen, J. B., Thorolfsdottir, R. B., Fritsche, L. G., Zhou, W., Skov, M. W., Graham, S. E., Herron, T. J., McCarthy, S., Schmidt, E. M., Sveinbjornsson, G., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0171-3 · Cited by 876
Braunwald, E. (2013) · JACC: Heart Failure · doi:10.1016/j.jchf.2012.10.002 · Cited by 730
“It has undergone Phase I and II testing and appears to be well-tolerated (in the absence of tachycardia) (135,136).”
BackgroundCardiac myosin activation with omecamtiv mecarbil in systolic heart failure
Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2025797 · Cited by 656
Self-citationSignaling effectors underlying pathologic growth and remodeling of the heart
van Berlo, J. H., Maillet, M., & Molkentin, J. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62839 · Cited by 445
Cleland, J. G., Teerlink, J. R., Senior, R., Nifontov, E. M., Mc Murray, J. J., Lang, C. C., Tsyrlin, V. A., Greenberg, B. H., Mayet, J., Francis, D. P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61126-4 · Cited by 333
Self-citation
Metadata
- Authors
- Teerlink, J. R., Clarke, C. P., Saikali, K. G., Lee, J. H., Chen, M. M., Escandon, R. D., Elliott, L., Bee, R., Habibzadeh, M. R., Goldman, J. H., Schiller, N. B., Malik, F. I., & Wolff, A. A.
- Affiliations
- San Francisco VA Medical Center (US)
- University of Manchester (GB)
- Cytokinetics (United States) (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 378
- Issue
- 9792
- Pages
- 667-675
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2143077915
- Cited by
- 262
- References
- 24
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 9 · 2023: 15 · 2022: 12 · 2021: 35 · 2020: 19 · 2019: 17 · 2018: 15 · 2017: 21 · 2016: 20 · 2015: 23 · 2014: 16 · 2013: 19 · 2012: 16
- FWCI
- 13.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cytokinetics
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- omecamtiv mecarbil, cardiac myosin activator, left ventricular systolic function, heart failure, dose escalation, maximum tolerated dose, myocardial ischemia, pharmacokinetics, pharmacodynamics, inotropic support, stroke volume, ejection fraction, fractional shortening
- MeSH terms
- Adult, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Infusions, Intravenous, Male, Middle Aged, Myocardial Contraction, Stroke Volume, Systole, Urea, Ventricular Function, Left, Cross-Over Studies, Maximum Tolerated Dose, Cardiac Myosins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. https://app.cochat.ai/papers/10.1016/s0140-6736(11)61219-1
- The paper
- Teerlink, J. R., Clarke, C. P., Saikali, K. G., Lee, J. H., Chen, M. M., Escandon, R. D., Elliott, L., Bee, R., Habibzadeh, M. R., Goldman, J. H., Schiller, N. B., Malik, F. I., & Wolff, A. A. (2011). Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. The Lancet. https://doi.org/10.1016/s0140-6736(11)61219-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.